Skip to content

ATOSSA THERAPEUTICS, INC.: 10-Q filed 2021-05-14

What ATOSSA THERAPEUTICS, INC. reported in its quarterly report filed 2021-05-14 (fiscal Q1 2021): 27 published measures, 57 facts as tagged in accession 0001437749-21-012213.

This filing

Form
10-Q (quarterly report)
Filed
2021-05-14
Fiscal period
fiscal Q1 2021
Accession
0001437749-21-012213 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ATOSSA THERAPEUTICS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2021-03-31141,080,546USD
At 2020-12-3142,839,453USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2021-03-31139,701,399USD
At 2020-12-3127,167,932USD
At 2020-03-3110,896,337USD
At 2019-12-3113,156,005USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2021-03-31137,573,593USD
At 2020-12-3139,553,671USD
At 2020-03-319,351,141USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-3,538,069USD90
2020-01-01 to 2020-03-31-2,947,420USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-4,408,788USD90
2020-01-01 to 2020-03-31-3,229,995USD91

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2021-01-01 to 2021-03-31102,428,710USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2021-03-31-112,165,700USD
At 2021-01-01-108,627,631USD
At 2020-12-31-111,898,992USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2021-03-3115,835USD
At 2020-12-3120,632USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-3,530,728USD90
2020-01-01 to 2020-03-31-2,937,009USD91

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2021-03-31141,031,313USD
At 2020-12-3142,770,175USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2021-03-311,379,147USD
At 2020-12-3115,671,521USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2021-03-31722,281USD
At 2020-12-311,588,613USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2021-03-318,917USD
At 2020-12-3113,375USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2021-01-01 to 2021-03-313,530,728USD90
2020-01-01 to 2020-03-312,937,009USD91

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2021-01-01 to 2021-03-311,378,487USD90
2020-01-01 to 2020-03-31938,620USD91

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2021-03-31120,824,368shares
At 2020-12-3147,548,835shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2021-01-01139,618,860USD
At 2020-12-31129,887,146USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2021-03-318,013USD
At 2020-12-3118,053USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2021-03-3116,468USD
At 2020-12-3117,218USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2021-03-31151,155USD
At 2020-12-3193,367USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-3,538,069USD90
2020-01-01 to 2020-03-31-2,947,420USD91

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-3,538,069USD90
2020-01-01 to 2020-03-31-2,947,420USD91

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2021-01-01 to 2021-03-312,152,241USD90
2020-01-01 to 2020-03-311,998,389USD91

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2021-01-01 to 2021-03-319,255USD90
2020-01-01 to 2020-03-3112,326USD91

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-7,341USD90
2020-01-01 to 2020-03-31-10,411USD91

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2021-01-01 to 2021-03-3110,700USD90
2020-01-01 to 2020-03-3114,700USD91

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2021-01-01 to 2021-03-31-866,332USD90
2020-01-01 to 2020-03-3163,081USD91

Inspect the source

Entity
ATOSSA THERAPEUTICS, INC. / CIK 0001488039
Captured
2026-09-20T09:09:43.864Z
SEC response SHA-256
1a9a7394baaf8eaa5fbb9f56ff3e675865210f784ada942417e365f62ac259f6

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001488039.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))